Lymphangiogenesis in Gastric Cancer regulated through Akt/mTOR-VEGF-C/VEGF-D axis

BMC Cancer

Volumn 15, Issue 1, 2015, Pages

  Chen, Hongxia ^a   Guan, Runnian ^b   Lei, Yupeng ^a   Chen, Jianyong ^c   Ge, Qi ^a   Zhang, Xiaoshen ^d   Dou, Ruoxu ^d   Chen, Hongyuan ^e   Liu, Hao ^d   Qi, Xiaolong ^a,d   Zhou, Xiaodong ^a   Chen, Changyan ^a,f  

^a NANCHANG UNIVERSITY   (China)

^b Kaiping Central Hospital   (China)

^c Jiangxi Provincial People's Hospital   (China)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e GUANGDONG PHARMACEUTICAL UNIVERSITY   (China)

^f NORTHEASTERN UNIVERSITY   (United States)

Author keywords

Akt mTOR; Gastric cancer; Lymphangiogenesis; VEGF

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE B; VASCULOTROPIN C; VASCULOTROPIN D; 2-(4-MORPHOLINYL)-8-PHENYL-4H-1-BENZOPYRAN-4-ONE; CHROMONE DERIVATIVE; ENZYME INHIBITOR; MORPHOLINE DERIVATIVE; TARGET OF RAPAMYCIN KINASE; TUMOR MARKER;

ANALYSIS OF VARIANCE; ARTICLE; CANCER INHIBITION; CELL GROWTH; CELL SURVIVAL; CHEMOLUMINESCENCE; CONTROLLED STUDY; CORRELATION ANALYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH VESSEL; LYMPHANGIOGENESIS; MAJOR CLINICAL STUDY; MORPHOLOGY; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; STOMACH CANCER; SUBMUCOSA; DRUG EFFECTS; FEMALE; MALE; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; STOMACH TUMOR;

BIOMARKERS, TUMOR; CHROMONES; ENZYME INHIBITORS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MORPHOLINES; NEOVASCULARIZATION, PATHOLOGIC; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS; TOR SERINE-THREONINE KINASES; VASCULAR ENDOTHELIAL GROWTH FACTOR C; VASCULAR ENDOTHELIAL GROWTH FACTOR D;

EID: 84928737258     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-015-1109-0     Document Type: Article

References (29)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9-29.
2. Yoo YA, Kang MH, Lee HJ, Kim BH, Park JK, Kim HK, et al. Sonic hedgehog pathway promotes metastasis and lymphangiogenesis via activation of Akt, EMT, and MMP-9 pathway in gastric cancer. Cancer Res. 2011;71:7061-70.
3. Liu C, Lu P, Lu Y, Xu H, Wang S, Chen J. Clinical implications of metastatic lymph node ratio in gastric cancer. BMC Cancer. 2007;7:200.
4. Brar SS, Mahar AL, Helyer LK, Swallow C, Law C, Paszat L, et al. Processes of care in the multidisciplinary treatment of gastric cancer: results of a RAND/UCLA expert panel. JAMA Surg. 2014;149:18-25.
5. Cunningham D, Chua YJ. East meets west in the treatment of gastric cancer. N Engl J Med. 2007;357:1863-5.
6. Karnezis T, Shayan R, Caesar C, Roufail S, Harris NC, Ardipradja K, et al. VEGF-D promotes tumor metastasis by regulating prostaglandins produced by the collecting lymphatic endothelium. Cancer Cell. 2012;21:181-95.
7. Ko YH, Jung CK, Lee MA, Byun JH, Kang JH, Lee KY, et al. Clinical significance of vascular endothelial growth factors (VEGF)-C and -D in resected non-small cell lung cancer. Cancer Res Treat. 2008;40:133-40.
8. He Y. Vascular endothelial cell growth factor receptor 3-mediated activation of lymphatic Eendothelium is crucial for tumor cell entry and spread via lymphatic vessels. Cancer Res. 2005;65:4739-46.
9. Chen H, Li L, Wang S, Lei Y, Ge Q, Lv N, et al. Reduced miR-126 expression facilitates angiogenesis of gastric cancer through its regulation on VEGF-A. Oncotarget. 2014;5:11873-5.
10. Zhou F, Chang Z, Zhang L, Hong YK, Shen B, Wang B, et al. Akt/Protein kinase B is required for lymphatic network formation, remodeling, and valve development. Am J Pathol. 2010;177:2124-33.
11. Kobayashi S, Kishimoto T, Kamata S, Otsuka M, Miyazaki M, Ishikura H. Rapamycin, a specific inhibitor of the mammalian target of rapamycin, suppresses lymphangiogenesis and lymphatic metastasis. Cancer Sci. 2007;98:726-33.
12. Scartozzi M, Giampieri R, Maccaroni E, Mandolesi A, Biagetti S, Alfonsi S, et al. Phosphorylated AKT and MAPK expression in primary tumours and in corresponding metastases and clinical outcome in colorectal cancer patients receiving irinotecan-cetuximab. J Transl Med. 2012;10:71.
13. Heikkinen T, Greco D, Pelttari LM, Tommiska J, Vahteristo P, Heikkilä P, et al. Variants on the promoter region of PTEN affect breast cancer progression and patient survival. Breast Cancer Res. 2011;13:R130.
14. Xu W, Huang JJ, Cheung PC. Extract of pleurotus pulmonarius suppresses liver cancer development and progression through inhibition of VEGF-induced PI3K/AKT signaling pathway. PLoS One. 2012;7:e34406.
15. Zhou XD, Chen HX, Guan RN, Lei YP, Shu X, Zhu Y, et al. Protein kinase B phosphorylation correlates with vascular endothelial growth factor A and microvessel density ingastric adenocarcinoma. J Int Med Res. 2012;40:2124-34.
16. Murakami D, Tsujitani S, Osaki T, Saito H, Katano K, Tatebe S, et al. Expression of phosphorylated Akt (pAkt) in gastric carcinoma predicts prognosis and efficacy of chemotherapy. Gastric Cancer. 2007;10:45-51.
17. Shi J, Yao D, Liu W, Wang N, Lv H, Zhang G, et al. Highly frequent PIK3CA amplification is associated with poor prognosis in gastric cancer. BMC Cancer. 2012;12:50.
18. Wang XL, Fang JP, Tang RY, Chen XM. Different significance between intratumoral and peritumoral lymphatic vessel density in gastric cancer: a retrospective study of 123 cases. BMC Cancer. 2010;10:299.
19. Han FH, Li HM, Zheng DH, He YL, Zhan WH. The effect of the expression of vascular endothelial growth factor (VEGF)-C and VEGF receptor-3 on the clinical outcome in patients with gastric carcinoma. Eur J Surg Oncol. 2010;36:1172-9.
20. Wang TB, Deng MH, Qiu WS, Dong WG. Association of serum vascular endothelial growth factor-C and lymphatic vessel density with lymph node metastasis and prognosis of patients with gastric cancer. World J Gastroenterol. 2007;13:1794-7.
21. Tsirlis TD, Kostakis A, Papastratis G, Masselou K, Vlachos I, Papachristodoulou A, et al. Predictive significance of preoperative serum VEGF-C and VEGF-D, independently and combined with Ca19-9, for the presence of malignancy and lymph node metastasis in patients with gastric cancer. J Surg Oncol. 2010;102:699-703.
22. Yu G, Wang J, Chen Y, Wang X, Pan J, Li G, et al. Overexpression of phosphorylated mammalian target of rapamycin predicts lymph node metastasis and prognosis of chinese patients with gastric cancer. Clin Cancer Res. 2009;15:1821-9.
23. Onogawa S, Kitadai Y, Amioka T, Kodama M, Cho S, Kuroda T, et al. Expression of vascular endothelial growth factor (VEGF)-C and VEGF-D in early gastric carcinoma: correlation with clinicopathological parameters. Cancer Lett. 2005;226:85-90.
24. Arigami T, Natsugoe S, Uenosono Y, Yanagita S, Ehi K, Arima H, et al. Vascular endothelial growth factor-C and -D expression correlates with lymph node micrometastasis in pN0 early gastric cancer. J Surg Oncol. 2009;99:148-53.
25. Shin JY, Kim JO, Lee SK, Chae HS, Kang JH. LY294002 may overcome 5-FU resistance via down-regulation of activated p-AKT in Epstein-Barr virus-positive gastric cancer cells. BMC Cancer. 2010;10:425.
26. Yao C, Liu J, Shao L. Rapamycin inhibits the proliferation and apoptosis of gastric cancer cells by down regulating the expression of survivin. Hepatogastroenterology. 2011;58:1075-80.
27. Zhang H, Fagan DH, Zeng X, Freeman KT, Sachdev D, Yee D. Inhibition of cancer cell proliferation and metastasis by insulin receptor downregulation. Oncogene. 2010;29:2517-27.
28. Wen J, Fu AF, Chen LJ, Xie XJ, Yang GL, Chen XC, et al. Liposomal honokiol inhibits VEGF-D-induced lymphangiogenesis and metastasis in xenograft tumor model. Int J Cancer. 2009;124:2709-18.
29. Shinriki S, Jono H, Ueda M, Ota K, Ota T, Sueyoshi T, et al. Interleukin-6 signaling regulates vascular endothelial growth factor-C synthesis and lymphangiogenesis in human oral squamous cell carcinoma. J Pathol. 2011;225:142-50.